Condition: Colon Cancer · Sponsor: Qilu Pharmaceutical Co., Ltd.
The goal of this clinical trial is to evaluate the efficacy of neoadjuvant QL1706 in participants with untreated T4N0 or Stage III (resectable), microsatellite instability high/ defective mismatch repair (MSI-H/dMMR) colon cancer
This description comes directly from the study's public registry record.
Ruihua Xu, PhD · +086-020-87343468 · xurh@sysucc.org.cn
Always discuss trial participation with your own doctor first.
| Affiliated Cancer Hospital of Sun Yat-sen University | Guangzhou, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06686576